Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting

Breast

Volumn 15, Issue 1 SUPPL., 2006, Pages 3-13

  Bhatnagar, Ajay S ^a  

^a World Wide Services Group Ltd   (Switzerland)

Author keywords

Adjuvant endocrine therapy; Advanced breast cancer; Aromastase inhibitors; Letrozole; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; EXEMESTANE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ADVANCED CANCER; BONE PAIN; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; HOT FLUSH; HUMAN; INOPERABLE CANCER; METASTASIS; NAUSEA; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; SURGICAL TECHNIQUE; THROMBOEMBOLISM; VAGINA BLEEDING;

EID: 33144455772     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2006.01.001     Document Type: Article

References (37)

1. European Parliamentary Group on Breast Cancer (EPGBC). Breast cancer facts: Breast cancer incidence in the EU. Available at: http://www.epgbc.org/BreastCancerFact.asp. Accessed June 26, 2005.
2. A.S. Bhatnagar C. Batzl A. Hausler K. Schieweck M. Lang P.F. Trunet Pharmacology of non-steroidal aromatase inhibitors J.R. Pasqualini B.S. Katzenellenbogen Hormone-dependent cancer 1996 Marcel Dekker New York 155-168
3. D. Simpson M.P. Curran C.M. Perry Letrozole: A review of its use in postmenopausal women with breast cancer Drugs 64 2004 1213-1230
4. P.E. Goss Breast cancer prevention-clinical trials strategies involving aromatase inhibitors J Steroid Biochem Mol Biol 86 2003 487-493
5. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: An overview of the randomised trials Lancet 351 1998 1451-1467
6. B. Fisher J.P. Costantino D.L. Wickerham et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371-1388
7. J. Cuzick T. Powles U. Veronesi et al. Overview of the main outcomes in breast-cancer prevention trials Lancet 361 2003 296-300
8. B. Fisher J. Dignam J. Bryant N. Wolmark Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial J Natl Cancer Inst 93 2001 684-690
9. B.P. Haynes M. Dowsett W.R. Miller J.M. Dixon A.S. Bhatnagar The pharmacology of letrozole J Steroid Biochem Mol Biol 87 2003 35-45
10. H. Mouridsen M. Gershanovich Y. Sun et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2001 2596-2606
11. J. Bonneterre A. Buzdar J.M. Nabholtz et al. Arimidex Writing Committee; Investigators Committee Members Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247-2258
12. T.N. Ansari A. Mahmood I. Hussain A. Samad Efficacy of letrozole for advanced breast cancer in postmenopausal patients J Coll Physicians Surg Pak 15 2005 204-206
13. P. Dombernowski I. Smith G. Falkson et. al. Letrozole a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 1998 453-461
14. M. Gershanovich H.A. Chaudri D. Campos et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3) Ann Oncol 9 1998 639-645
15. C. Rose O. Vtoraya A. Pluzanska et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole Eur J Cancer 39 2003 2318-2327
16. R. Paridaens P. Therasse L. Dirix et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group J Clin Oncol 22 Suppl 14 2004 [Abstract 515]
17. J.M. Nabholtz J. Bonneterre A. Buzdar J.F. Robertson B. Thürlimann Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results Eur J Cancer 39 2003 1684-1689
18. R. Paridaens L. Dirix C. Lohrisch et al. European Organization for the Research and Treatment of Cancer (EORTC)-Investigational Drug Branch for Breast Cancer (IDBBC) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann Oncol 14 2003 1391-1398
19. H. Mouridsen M. Gershanovich Y. Sun et. al. A phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group J Clin Oncol 21 2003 2101-2109
20. Femara Prescribing Information. East Hanover, NJ: Novartis Pharmaceutical Corporation; November 2004.
21. J. Huober U. Krainick-Strobel R. Kurek D. Wallwiener Neoadjuvant endocrine therapy in primary breast cancer Clin Breast Cancer 5 2004 341-347
22. V. Semiglazov A. Kletsel V. Semiglazov et. al. Exemestane (E) versus tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) J Clin Oncol 23 Suppl 16 2005 11S [Abstract 530]
23. I. Smith M. Dowsett Comparison of anastrozole versus tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial Breast Cancer Res Treat 82 Suppl 1 2003 1
24. I.E. Smith M. Dowsett S.R. Ebbs et. al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate PReoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 2005 5108-5116
25. M. Baum A.U. Budzar J. Cuzick et al. ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen, alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131-2139
26. W. Eiermann S. Paepke J. Appfelstaedt et al. Letrozole Neo-Adjuvant Breast Cancer Study Group Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study Ann Oncol 12 2001 1527-1532
27. M.J. Ellis A. Coop B. Singh et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 2001 3808-3816
28. M.J. Ellis A. Coop B. Singh et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status Cancer Res 63 2003 6523-6531
29. Murray J, Young O, Renshaw L, et al. Letrozole and anastrozole: A pre-operative study of their effects on ER positive breast cancers in postmenopausal women. Presented at the 27th annual San Antonio breast cancer symposium, December 2004 [Abstract 406].
30. M.J. Ellis Y. Tao O. Young et. al. Estrogen-independent cell proliferation occurs in the majority of estrogen receptor positive (ER+)/ HER2 gene-amplified primary breast cancers: Evidence from a combined analysis of two independent neoadjuvant letrozole studies J Clin Oncol 23 Suppl 16 2005 846SS [Abstract 9538]
31. Young O, Murray J, Renshaw L, et al. Neoadjuvant letrozole is equally effective in HER2 positive and negative breast cancers. Presented at the 2004 San Antonio breast cancer symposium, December 2004 [Abstract 411].
32. W.R. Miller L. Renshaw A. Larionov et al. Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole J Clin Oncol 23 Suppl 16 2005 198S [Abstract 3025]
33. Miller WR, Renshaw L, Murray J, et al. Microarray analysis of sequential tumor biopsies from patients receiving neoadjuvant therapy is able to distinguish sub-populations of breast cancers with differential response to the aromatase inhibitor, letrozole. Presented at the 27th annual San Antonio breast cancer symposium, December 2004 [Abstract 1020].
34. S. Paepke A. Tulusan L. Kiesel et al. A multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer Proc Am Soc Clin Oncol 22 2003 80 [Abstract 321]
35. Renshaw L, Murray J, Young O, Cameron D, Miller WR, Dixon JM. Is there an optimal duration of neoadjuvant letrozole therapy? Presented at the 27th the San Antonio breast cancer symposium, December 2004 [Abstract 405].
36. J. Geisler B. Haynes G. Anker M. Dowsett P.E. Lonning Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 2002 751-757
37. A. Bernardi C. Zamagni F. Di Fabio E. Piana A. Martoni F. Vecchi Randomized comparative study on estrogen suppression induced by 3 different aromatase inhibitors in postmenopausal patients with advanced breast cancer Proc Amer Soc Clin Oncol 2002 [Abstract 217]